Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,250

The quest to overcome resistance to EGFR-targeted therapies in cancer

Chong, C. R., & Janne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,076

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

Oser, M. G., Niederst, M. J., Sequist, L. V. D., & Engelman, J. A. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71180-5 · Cited by 974

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms11815 · Cited by 657

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Niederst, M. J., Sequist, L. V., Poirier, J. T., Mermel, C. H., Lockerman, E. L., Garcia, A. R., Katayama, R., Costa, C., Ross, K. N., Moran, T., et al. (2015) · Nature Communications · doi:10.1038/ncomms7377 · Cited by 647

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

Finlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500973a · Cited by 636

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0314 · Cited by 620

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

Costa, D. B., Shaw, A. T., Ou, S. I., Solomon, B., Riely, G. J., Ahn, M., Zhou, C., Shreeve, S. M., Selaru, P., Polli, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0539 · Cited by 608

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

Niederst, M. J., Hu, H., Mulvey, H. E., Lockerman, E. L., Garcia, A. R., Piotrowska, Z., Sequist, L. V., & Engelman, J. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0560 · Cited by 583

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding

Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507

The EGFR Family: Not So Prototypical Receptor Tyrosine KinasesPreprint

Lemmon, M. A., Lemmon, M. A., & Ferguson, K. M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020768 · Cited by 472

Genomic alterations in lung adenocarcinoma

Devarakonda, S. H. K., Morgensztern, D., & Govindan, R. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00077-7 · Cited by 423

Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma

Furnari, F. B., Cloughesy, T. F., Cavenee, W. K., & Mischel, P. S. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3918 · Cited by 389

Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR -Mutant Lung Cancer with and without T790M Mutations

Janjigian, Y. Y., Smit, E. F., Groen, H. J. M., Horn, L., Gettinger, S., Camidge, D. R., Riely, G. J., Wang, B., Fu, Y., Chand, V. K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0326 · Cited by 362

Refining the treatment of NSCLC according to histological and molecular subtypes

Thomas, A., Liu, S. V., Subramaniam, D. S., & Giaccone, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.90 · Cited by 323

Chimeric antigen receptor T cells: a novel therapy for solid tumors

Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0444-9 · Cited by 314

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.

Stewart, E., Tan, S. Z., Liu, G., & Tsao, M. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.11.06 · Cited by 314

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Qi, S., Dong, J., Xu, Z., Cheng, X., Zhang, W., & Qin, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.692574 · Cited by 306

Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies

Apicella, M., Giannoni, E., Fiore, S., Ferrari, K. J., Fernández-Pérez, D., Isella, C., Granchi, C., Minutolo, F., Sottile, A., Comoglio, P. M., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.006 · Cited by 299

CD74–NRG1 Fusions in Lung Adenocarcinoma

Fernandez‐Cuesta, L., Plenker, D., Osada, H., Sun, R., Menon, R., Leenders, F., Ortiz‐Cuaran, S., Peifer, M., Bos, M. C. A., Daßler, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0633 · Cited by 295

Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes

Yang, C., Lin, M., Chang, Y., Wu, C., & Yang, P. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.018 · Cited by 288

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations

Lin, A., Wei, T., Meng, H., Luo, P., & Zhang, J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1062-7 · Cited by 266

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

Ortiz‐Cuaran, S., Scheffler, M., Plenker, D., Dahmen, L., Scheel, A. H., Fernandez‐Cuesta, L., Meder, L., Lovly, C. M., ten Persigehl, T., Merkelbach‐Bruse, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1915 · Cited by 264

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M. C., Paz-Ares, L. G., Reck, M., Smit, E. F., Syrigos, K., Stahel, R. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu123 · Cited by 250

FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung Cancer

Kazandjian, D. G., Blumenthal, G. M., Yuan, W., He, K., Keegan, P., & Pazdur, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2266 · Cited by 245

Biology and evolution of poorly differentiated neuroendocrine tumors

Rickman, D. S., Beltran, H., Demichelis, F., & Rubin, M. A. (2017) · Nature Medicine · doi:10.1038/nm.4341 · Cited by 230

Recent Clinical Advances in Lung Cancer Management

Johnson, D. H., Schiller, J. H., & Bunn, P. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1228 · Cited by 222

Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR

Watanabe, M., Kawaguchi, T., Isa, S.-I., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2151 · Cited by 216

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

Blakely, C. M., Pazarentzos, E., Olivas, V., Asthana, S., Yan, J. J., Tan, I., Hrustanovic, G., Chan, E., Lin, L., Neel, D. S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.012 · Cited by 204

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?

Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.003 · Cited by 186

PROTACs: A novel strategy for cancer therapy

Liu, J., Ma, J., Liu, Y., Xia, J., Li, Y., Wang, Z. P., & Wei, W. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.006 · Cited by 186

A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

Nilsson, M. B., Sun, H., Robichaux, J., Pfeifer, M., McDermott, U., Travers, J., Diao, L., Xi, Y., Tong, P., Shen, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4589 · Cited by 177

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1 -Rearranged Lung Cancer

Drilon, A. E. D. C., Somwar, R., Wagner, J. P., Vellore, N. A., Eide, C. A., Zabriskie, M. S., Arcila, M. E., Hechtman, J. F., Wang, L., Smith, R. S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2013 · Cited by 171

PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung

Kim, S., Koh, J., Kim, M., Kwon, D., Go, H., Kim, Y. A., Jeon, Y. K., & Chung, D. H. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.07.007 · Cited by 168

EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies

Jia, Y., Li, X., Jiang, T., Zhao, S., Zhao, C., Zhang, L., Liu, X., Shi, J., Qiao, M., Luo, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32191 · Cited by 164

Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status

Koh, J., Go, H., Keam, B., Kim, M., Nam, S. J., Kim, T. M., Lee, S., Min, H. S., Kim, Y. T., Kim, D., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.63 · Cited by 160

Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations

Gazdar, A. F., Robinson, L. D., Oliver, D., Xing, C., Travis, W. D., Soh, J., Toyooka, S., Watumull, L. M., Xie, Y., Kernstine, K. H., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000130 · Cited by 156

Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)

Lee, J. Y., Qing, X., Wei, X., Yali, B., Chi, S., Bak, S. H., Lee, H. Y., Sun, J., Lee, S., Ahn, J. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6874 · Cited by 159

Intratumoral Heterogeneity in EGFR -Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition

Soucheray, M., Capelletti, M., Pulido, I., Kuang, Y., Paweletz, C. P., Becker, J. H., Kikuchi, E., Xu, C., Patel, T. B., Al‐Shahrour, F., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0377 · Cited by 157

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer

Ricordel, C., Friboulet, L., Facchinetti, F., & Soria, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx705 · Cited by 156

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?

Takeda, M., & Nakagawa, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010146 · Cited by 154

Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non–Small Cell Lung Cancer

Rosa, V. D., Iommelli, F., Monti, M., Fonti, R., Votta, G., Stoppelli, M. P., & Vecchio, S. D. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0375 · Cited by 152

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer

Ichihara, E., Westover, D., Meador, C. B., Yan, Y., Bauer, J. A., Lu, P., Ye, F., Kulick, A., de Stanchina, E., McEwen, R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2300 · Cited by 150

Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer

Cheng, N., Cai, W., Ren, S., Li, X., Wang, Q., Pan, H., Zhao, M., Li, J., Zhang, Y., Zhao, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4361 · Cited by 150

LncRNA UCA1 in anti-cancer drug resistance

Wang, H., Guan, Z., He, K., Qian, J., Cao, J., & Teng, L. (2017) · Oncotarget · doi:10.18632/oncotarget.18344 · Cited by 148

EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment

Madeddu, C., Donisi, C., Liscia, N., Lai, E., Scartozzi, M., & Macciò, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126489 · Cited by 161

U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations

Khozin, S., Blumenthal, G. M., Jiang, X., He, K., Boyd, K. K., Murgo, A. J., Justice, R. L., Keegan, P., & Pazdur, R. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0089 · Cited by 143

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

Wang, J., Wang, B., Chu, H., & Yao, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s106399 · Cited by 143

Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer

Davies, K. D., Mahale, S., Astling, D. P., Aisner, D. L., Le, A. T., Hinz, T. K., Vaishnavi, A., Bunn, P. A., Heasley, L. E., Tan, A. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082236 · Cited by 128

The Evolution of Therapies in Non-Small Cell Lung Cancer

Boolell, V., Alamgeer, M., Watkins, D. N., & Ganju, V. (2015) · Cancers · doi:10.3390/cancers7030864 · Cited by 130

Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non‐small‐cell lung cancer

Micke, P., Mattsson, J. S. M., Edlund, K., Lohr, M., Jirström, K., Berglund, A., Botling, J., Rahnenführer, J., Marincevic, M., Pontén, F., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28857 · Cited by 127

Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data

Jorge, S. E., Kobayashi, S. S., & Costa, D. B. (2014) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20144099 · Cited by 127

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer

Suzawa, K., Offin, M. D., Lu, D., Kurzatkowski, C., Vojnic, M., Smith, R. S., Sabari, J. K., Tai, H., Mattar, M. S., Khodos, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1640 · Cited by 129

Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma

Lin, C., Chen, X., Li, M., Liu, J., Qi, X., Yang, W., Zhang, H., Cai, Z., Dai, Y., & Ouyang, X. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.02.002 · Cited by 119

Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review

Meng, T., Jin, J., Jiang, C., Huang, R., Yin, H., Song, D., & Cheng, L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00030 · Cited by 114

Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights

Meador, C. B., & Hata, A. N. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107522 · Cited by 119

Recent progress on third generation covalent EGFR inhibitors

Cheng, H., Nair, S. K., & Murray, B. W. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.067 · Cited by 110

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance

Nilsson, M. B., Yang, Y., Heeke, S., Patel, S. A., Poteete, A., Udagawa, H., Elamin, Y. Y., Moran, C. A., Kashima, Y., Arumugam, T., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.007 · Cited by 112

Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer

Pan, H., Jiang, T., Cheng, N., Wang, Q., Ren, S., Li, X., Zhao, C., Zhang, L., Cai, W., & Zhou, C. (2016) · Oncotarget · doi:10.18632/oncotarget.10521 · Cited by 107

The Impact of Genomic Changes on Treatment of Lung Cancer

Cardarella, S., & Johnson, B. E. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201305-0843pp · Cited by 103

TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer

Gong, K., Guo, G., Gerber, D. E., Gao, B., Peyton, M., Huang, C., Minna, J. D., Hatanpaa, K. J., Kernstine, K., Cai, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96148 · Cited by 98

Discovery of N-((3 R,4 R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1 H-pyrazol-4-yl)amino)-9-methyl-9 H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR

Planken, S., Behenna, D. C., Nair, S. K., Johnson, T. O., Nagata, A., Almaden, C., Bailey, S., Ballard, T. E., Bernier, L., Cheng, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01894 · Cited by 97

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients

Matsuo, N., Azuma, K., Sakai, K., Hattori, S., Kawahara, A., Ishii, H., Tokito, T., Kinoshita, T., Yamada, K., Nishio, K., et al. (2016) · Scientific Reports · doi:10.1038/srep36458 · Cited by 97

Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer

Yamaguchi, N., Lucena-Araujo, A. R., Nakayama, S., de Figueiredo‐Pontes, L. L., Gonzalez, D. A., Yasuda, H., Kobayashi, S. S., & Costa, D. B. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.09.019 · Cited by 96

Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants

Cheng, H., Nair, S. K., Murray, B. W., Almaden, C., Bailey, S., Baxi, S. M., Behenna, D. C., Cho-Schultz, S., Dalvie, D., Dinh, D. M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01633 · Cited by 98

EGFR mutations in lung cancer: from tissue testing to liquid biopsy

Fenizia, F., Luca, A. D., Pasquale, R., Sacco, A., Forgione, L., Lambiase, M., Iannaccone, A., Chicchinelli, N., Franco, R., Rossi, A., et al. (2015) · Future Oncology · doi:10.2217/fon.15.23 · Cited by 95

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation

Ji, M. Q., Liu, Y., Li, Q., Li, X., Zhao, W., Zhang, H., Zhang, X., Jiang, J., & Wu, C. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-014-0373-0 · Cited by 95

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma

Grève, J. D., Morán, T., Graas, M.-P., Galdermans, D., Vuylsteke, P., Canon, J.-L. R., Schallier, D. C. C., Decoster, L., Teugels, E., Massey, D., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.013 · Cited by 91

Drug Resistance to EGFR Inhibitors in Lung Cancer

Tetsu, O., Hangauer, M. J., Phuchareon, J., Eisele, D. W., & McCormick, F. P. (2016) · Chemotherapy · doi:10.1159/000443368 · Cited by 88

Interdependent epidermal growth factor receptor signalling and trafficking

Jones, S., & Rappoport, J. Z. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.03.014 · Cited by 90

Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity

Guo, J., Liang, Y., Xue, D., Shen, J., Cai, Y., Zhu, J., Fu, Y., & Peng, H. (2021) · Cell Research · doi:10.1038/s41422-021-00543-4 · Cited by 89

Management and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations

Gerber, D. E., Gandhi, L., & Costa, D. B. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e353 · Cited by 89

Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer

Cimas, F. J., Niza, E., Juan, A., Noblejas‐López, M. D. M., Bravo, I., Lara‐Sánchez, A., Alonso‐Moreno, C., & Ocaña, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100986 · Cited by 90

Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target

Qie, S., & Sang, N. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02370-w · Cited by 90

EGFR Regulates the Development and Microarchitecture of Intratumoral Angiogenic Vasculature Capable of Sustaining Cancer Cell Intravasation

Minder, P., Zając, E., Quigley, J. P., & Deryugina, E. I. (2015) · Neoplasia · doi:10.1016/j.neo.2015.08.002 · Cited by 87

Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway

Leone, A., Roca, M. S., Ciardiello, C., Terranova-Barberio, M., Vitagliano, C., Ciliberto, G., Mancini, R., Gennaro, E. D., Bruzzese, F., & Budillon, A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.07.155 · Cited by 84

Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement

Huang, X., Li, E., Shen, H., Wang, X., Tang, T., Zhang, X., Xu, J., Tang, Z., Guo, C., Bai, X., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00152 · Cited by 82

InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma

Ma, Y., Tang, N., Thompson, R. C., Mobley, B. C., Clark, S. W., Sarkaria, J. N., & Wang, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1677 · Cited by 84

IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer

Liu, Y., Chang, T., Tsai, M., Wu, S., Tsai, T.-H., Chen, H., Yu, S., Yang, J. C., & Shih, J. (2015) · Oncotarget · doi:10.18632/oncotarget.3389 · Cited by 79

Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma

Koh, J., Kim, S., Kim, M.-Y., Go, H., Jeon, Y. K., & Chung, D. H. (2017) · Oncotarget · doi:10.18632/oncotarget.14632 · Cited by 77

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer

Isozaki, H., Takigawa, N., & Kiura, K. (2015) · Cancers · doi:10.3390/cancers7020763 · Cited by 76

Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study

Wang, W., Xu, C., Chen, H., Jia, J., Wang, L., Feng, H., Wang, H., Song, Z., Yang, N., & Zhang, Y. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.03.006 · Cited by 75

KPT-330 has antitumour activity against non-small cell lung cancer

Sun, H., Hattori, N., Chien, W., Sun, Q., Sudo, M., E-Ling, G. L., Ding, L., Lim, S. L., Shacham, S., Kauffman, M. G., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.260 · Cited by 74

Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors

Dorantes-Heredia, R., Ruiz-Morales, J. M., & Cano-García, F. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.07.10 · Cited by 73

Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1

Pirazzoli, V., Nebhan, C., Song, X., Wurtz, A., Walther, Z., Cai, G., Zhao, Z., Jia, P., de Stanchina, E., Shapiro, E. M., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.014 · Cited by 71

Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)

Takahama, T., Sakai, K., Takeda, M., Azuma, K., Hida, T., Hirabayashi, M., Oguri, T., Tanaka, H., Ebi, N., Sawa, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11303 · Cited by 73

Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation

Isobe, K., Hata, Y., Tochigi, N., Kaburaki, K., Kobayashi, H., Makino, T., Otsuka, H., Sato, F., Ishida, F., Kikuchi, N., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000125 · Cited by 70

In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Sjin, R. T. T., Lee, K., Walter, A. O., Dubrovskiy, A., Sheets, M. P., Martin, T. S., Labenski, M., Zhu, Z., Tester, R. W., Karp, R., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0966 · Cited by 68

LncRNA SNHG15 regulates EGFR-TKI acquired resistance in lung adenocarcinoma through sponging miR-451 to upregulate MDR-1

Huang, J., Pan, B., Xia, G., Zhu, J., Li, C., & Feng, J. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2683-x · Cited by 68

Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant–Positive Non–Small Cell Lung Cancer

Song, J., Wang, L., Ng, N. N., Zhao, M., Shi, J., Wu, N., Li, W., Liu, Z., Yeom, K. W., & Tian, J. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.30442 · Cited by 70

Gefitinib: a review of its use in adults with advanced non-small cell lung cancer

Dhillon, S. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0358-9 · Cited by 68

Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies

Meador, C. B., Micheel, C., Levy, M. A., Lovly, C. M., Horn, L., Warner, J. L., Johnson, D. B., Zhao, Z., Anderson, I. A., Sosman, J. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1591 · Cited by 68

Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1

Lü, Y., Liu, Y., Oeck, S., & Glazer, P. M. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0637 · Cited by 68

Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer

Kuwano, M., Sonoda, K., Murakami, Y., Watari, K., & Ono, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.002 · Cited by 66

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Li, J., Chen, X., Lü, A., & Liang, C. (2023) · The Innovation · doi:10.1016/j.xinn.2023.100413 · Cited by 68

The design of peptide-amphiphiles as functional ligands for liposomal anticancer drug and gene delivery

Kuang, H., Ku, S. H., & Kokkoli, E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.08.005 · Cited by 66

Discovery of N -(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC

Chen, Y., Wu, J., Wang, A., Qi, Z., Jiang, T., Cheng, C., Zou, F., Hu, C., Wang, W., Wu, H., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.035 · Cited by 67

Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities – Part 1

Das, D., Xie, L., Wang, J., Xu, X., Zhang, Z., Shi, J., Le, X., & Hong, J. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.056 · Cited by 65

Impact of EGFR mutations on treatment of non-small cell lung cancer

Johnson, B. E., Jackman, D. M., & Janne, P. A. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0309-3 · Cited by 7

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management

Noronha, V., Rajendra, A., Joshi, A., Patil, V., Menon, N. N., & Prabhash, K. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_51_19 · Cited by 64

New Treatment Strategy for Patients with EGFR -Mutant Lung Cancer

Ninomiya, T., Takigawa, N., Toyooka, S., Hotta, K., Tanimoto, M., & Kiura, K. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.63

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer

Chang, S., Chang, C., & Shih, J. (2011) · Cancers · doi:10.3390/cancers3022667 · Cited by 6

Overcoming Resistance to EGF Receptor Tyrosine Kinase Inhibitors in EGFR -mutated NSCLC

Saad, S., Huang, K., & Halmos, B. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.35 · Cited by 1